WySE Products Launches Total Pet Kitchen, The First-of-Its-Kind Multicooker for Fresh Pet Food Preparation at Home
Englewood Cliffs, NJ, June 23, 2025 (GLOBE NEWSWIRE) — WySE Products LLC, a company committed to redefining pet nutrition, is pleased to announce the launch of Total Pet Kitchen Multicooker (TPK), the first-of-its-kind countertop appliance designed specifically for cooking and dispensing healthy food for pets using human-grade ingredients.
WySE Products Total Pet Kitchen Multicooker
The Total Pet Kitchen multicooker was developed over two years through collaboration with chefs, veterinarians, pet nutritionists, engineers, and pet owners. The team focused on addressing common barriers to home-prepared pet meals, including time constraints, nutritional uncertainty, and inconsistent results. The result is a patent-pending appliance designed to simplify fresh pet food preparation at home. Every component was designed with a focus on safety, efficiency, and user experience.
'Fresh food can make a difference in a pet's health, but until now, there wasn't an easy, practical way to prepare those meals at home,' said Paul McGrath, a representative for TPK. 'That's why we invested significant time in development to create a system that helps pet owners prepare meals with real, recognizable ingredients that get great results no matter what your skill level in the kitchen. Total Pet Kitchen is more than a cooker, it's a movement to bring real, whole food back into our pets' lives in a way that's practical for modern households.'
Built for Pet Health and Everyday Use
The TPK multicooker offers pet owners a smarter, more efficient way to prepare fresh meals without the time, mess, and guesswork of traditional home cooking. According to the company, meals made in the Total Pet Kitchen can save pet owners up to 75% in costs as compared to subscription delivery food services. This all-in-one appliance combines mixing, cooking, and extrusion into a single streamlined process to make it easier to serve nutritious pet food made from real ingredients.
Key features: A 4.5-qt ceramic-coated inner pot that's BPA-, PTFE, and PFOA-free
Easy-read control panel with illuminated progress indicators.
Four programmable settings for beef, chicken, fish, and grain-free meals.
Easily removable inner cooking components are dishwasher safe.
Automatic extrusion and dispensing of cooked food mixture.
Recipe support through video and written guides.
The device can prepare up to a week's worth of food in a single batch, helping pet owners save time.
Expert-Approved Recipes and Ongoing Support
Beyond the multicooker, Total Pet Kitchen offers a growing library of expert-reviewed recipes and guides available through online videos and written resources. All content is developed and approved in collaboration with TPK's veterinary consultant team to help pet owners prepare meals that are balanced, safe, and tailored to their dog's needs, whether for a full home-cooked diet or as a healthy supplement to existing meals.
Processed pet foods often contain low-quality ingredients, fillers, artificial preservatives, and additives that offer limited nutritional value. Switching to fresh, home-prepared food, even as a partial replacement, can significantly improve a pet's diet and potentially reduce long-term costs associated with poor nutrition, such as frequent vet visits and chronic health issues.
To support pet owners in this transition, Total Pet Kitchen provides comprehensive educational materials, from meal planning guides to step-by-step cooking tutorials. These resources are updated regularly based on in-house testing and user feedback to ensure they remain practical, accessible, and aligned with the evolving needs of the modern pet household.
Responding to Growing Demand
Recent trends in pet care point to increasing awareness about the ingredients in commercial pet food. More owners are seeking alternatives that align with their own dietary values, favoring fresh, whole foods over ultra-processed options.
This shift in consumer priorities has created a need for tools that support healthier feeding practices without adding complexity to daily routines. The TPK multicooker meets this demand with its combination of food-safe materials, automated cooking programs, and an easy-to-clean design, offering a practical and user-friendly option for households focused on improving pet wellness.
'Launching the Total Pet Kitchen multicooker reflects our ongoing commitment to improving how pets are fed at home,' said McGrath. 'It's a solution developed for modern pet owners who value health, safety, and simplicity, and we're excited to make it widely available.'
The company notes this launch is just the beginning. Future updates will continue to expand recipe offerings, refine functionality, and add new content to support pet owners in keeping their pets healthy and thriving.
Availability
The Total Pet Kitchen multicooker is available for purchase at the company website and Amazon. It's also gearing up to roll out in select retailers in the near future. For more information, updates, or to view the complete product specifications, visit the official website at http://www.totalpetkitchen.com or contact Total Pet Kitchen by phone at (201) 603-2597.
About Total Pet Kitchen
Total Pet Kitchen is a brand dedicated to making fresh, homemade meals easy for pet owners. Born from personal experiences with pet health challenges, the company developed the first all-in-one multicooker designed specifically for preparing pet food using real, human-grade ingredients. With features tailored for safety, simplicity, and convenience, Total Pet Kitchen empowers pet parents to take control of their pets' nutrition. The brand also offers vet-reviewed recipes, nutritional guides, and instructional videos to support every step of the journey. Total Pet Kitchen is a trademark of WySE Products LLC.
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
Ahmedabad Plane Crash
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
21 minutes ago
- Yahoo
iBio Presents Next-Generation Obesity and Cardiometabolic Pipeline Candidates on June 24 Conference Call
Review of promising Myostatin and Activin E antibody data iBio to announce 3rd target in Astral Bio Collaboration Conference call Tuesday, June 24 at 8:30 a.m. ET SAN DIEGO, June 23, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (Nasdaq: IBIO), an AI-driven innovator of precision antibody therapies, today announced the Company will host a conference call on Tuesday, June 24, at 8:30 a.m. ET to review its latest advances in obesity and cardiometabolic disease treatments and announce a third target in the AstralBio Collaboration in addition to Myostatin and Activin Brenner, DVM, Ph.D., iBio's CEO and Chief Scientific Officer, will outline how iBio is pioneering the next generation of antibody medicines—targeted, longer-lasting, and potentially better tolerated therapies with more sustainable efficacy. Dr. Brenner will present a strategic overview of the obesity strategy, including details on their long acting Myostatin, IBIO-600, new preclinical data on Activin E and, more safe and effective treatment webcast of the live call may be accessed on the Investors section of the iBio website at A replay of the webcast will be available on the iBio website for approximately 60 days following the join the live call, participants need to access this link for dial-in numbers and a unique participation code. About iBio, Inc. iBio (Nasdaq: IBIO) is a cutting-edge biotech company leveraging AI and advanced computational biology to develop next-generation biopharmaceuticals for cardiometabolic diseases, obesity, cancer and other hard-to-treat diseases. By combining proprietary 3D modeling with innovative drug discovery platforms, iBio is creating a pipeline of breakthrough antibody treatments to address significant unmet medical needs. Our mission is to transform drug discovery, accelerate development timelines, and unlock new possibilities in precision medicine. For more information, visit or follow us on LinkedIn. Forward-Looking Statements Any statements contained in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute 'forward-looking statements.' These statements include statements regarding pioneering the next generation of antibody medicines, which are potentially better tolerated therapies with more sustainable efficacy, and Activin E and amylin agonist, which are promising pathways for more safe and effective treatment options. The words 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' 'would' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including iBio's ability to obtain regulatory approvals for commercialization of its product candidates, or to comply with ongoing regulatory requirements; regulatory limitations relating to iBio's ability to promote or commercialize its product candidates for specific indications; acceptance of iBio's product candidates in the marketplace and the successful development, marketing or sale of products; and whether iBio will incur unforeseen expenses or liabilities or other market factors; and the other factors discussed in iBio's filings with the SEC including its Annual Report on Form 10-K for the year ended June 30, 2024 and its subsequent filings with the SEC on Forms 10-Q and 8-K. The information in this release is provided only as of the date of this release, and iBio undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law. Corporate Contact: iBio, Inc. Investor Relations ir@ Media Contacts: Ignacio Guerrero-Ros, Ph.D., or David Schull Russo Partners, LLC (858) 717-2310 or (646) 942-5604
Yahoo
21 minutes ago
- Yahoo
Plymouth Announces Strategic Acquisition of a 1.95-million-square-foot Ohio Industrial Portfolio
BOSTON, June 23, 2025 (GLOBE NEWSWIRE) -- Plymouth Industrial REIT, Inc. (NYSE: PLYM) (the 'Company' or 'Plymouth') today announced the acquisition of a 1.95-million-square-foot portfolio of industrial properties located across Columbus, Cincinnati, and Cleveland, Ohio for a total purchase price of $193.0 million. The 21-building portfolio comprises highly functional industrial assets with strong infill locations and desirable physical features including high clear heights, ample truck loading, updated lighting, and modern office finishes. The portfolio is currently 97% leased to 75 tenants with a weighted average remaining lease term of 2.47 years. In-place rents are approximately 22% below current market rates, which we believe offers substantial upside potential upon lease rollover. The purchase price reflects a 25%-plus discount to today's replacement cost. With this acquisition, Plymouth now owns over 12 million square feet of industrial space in Ohio. The portfolio will be operated from the Company's Columbus office, which is staffed by a team of nine experienced property management professionals. This acquisition further strengthens Plymouth's regional footprint and aligns with its strategy of acquiring well-located, income-generating industrial assets with embedded growth potential. Anthony Saladino, President and CFO of Plymouth Industrial REIT, noted, 'This transaction reflects our continued success in deploying strategic capital into high-quality, functional industrial real estate at compelling economics. By adding scale in our core markets and leveraging our vertically integrated platform, we believe we are well-positioned to drive long-term value creation and deliver strong leasing outcomes across the portfolio.' About PlymouthPlymouth Industrial REIT, Inc. (NYSE: PLYM) is a full service, vertically integrated real estate investment company focused on the acquisition, ownership and management of single and multi-tenant industrial properties. Our mission is to provide tenants with cost-effective space that is functional, flexible and safe. Forward-Looking Statements This press release includes 'forward-looking statements' that are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and of Section 21E of the Securities Exchange Act of 1934. The forward-looking statements in this release do not constitute guarantees of future performance. Investors are cautioned that statements in this press release, which are not strictly historical statements, including, without limitation, statements regarding management's plans, objectives and strategies, statements regarding NOI yields, as well as statements regarding the timing of the consummation of the transactions, if at all, and the anticipated benefits therefrom, constitute forward-looking statements. Such forward-looking statements are subject to a number of known and unknown risks and uncertainties that could cause actual results to differ materially from those anticipated by the forward-looking statements, many of which may be beyond our control. Forward-looking statements generally can be identified by the use of forward-looking terminology such as 'may,' 'plan,' 'seek,' 'will,' 'expect,' 'intend,' 'estimate,' 'anticipate,' 'believe' or 'continue' or the negative thereof or variations thereon or similar terminology. Any forward-looking information presented herein is made only as of the date of this press release, and we do not undertake any obligation to update or revise any forward-looking information to reflect changes in assumptions, the occurrence of unanticipated events, or otherwise. CONTACT: Contacts: Plymouth Industrial REIT, Inc. Ethan Farris IR@ while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
32 minutes ago
- Yahoo
Terns Pharmaceuticals Presents Positive Data from Phase 1 Study of TERN-601 Once-daily Oral GLP-1R Agonist for Treatment of Obesity at 85th Annual American Diabetes Association Scientific Sessions
Phase 1 clinical study of TERN-601 demonstrated differentiated profile in 28-day study; topline data were presented in September 2024 Phase 2 FALCON clinical trial of TERN-601 completed enrollment; 12-week data expected in 4Q 2025 FOSTER CITY, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ('Terns' or the 'Company') (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that data from the completed Phase 1 study of TERN-601, a novel once-daily oral GLP-1R agonist, will be highlighted at the American Diabetes Association (ADA) 85th Scientific Sessions, taking place June 20-23, 2025, in Chicago, IL. 'We are thrilled to be selected for an oral presentation at ADA to highlight additional data from the 28-day Phase 1 study of TERN-601 demonstrating its differentiated profile among oral GLP1-R agonists,' said Amy Burroughs, chief executive officer of Terns. 'In addition, we are pleased to share the recent completion of enrollment for our Phase 2 FALCON trial where the key objectives of the trial are to demonstrate TERN-601's competitive weight loss at 12-weeks, a class leading safety and tolerability profile, and the simplest dose titration amongst GLP-1R agonist therapies.' Topline data from the Phase 1 clinical study being presented at ADA were reported in September 2024 and provided the recommended doses taken forward in the ongoing Phase 2 FALCON study, which recently completed enrollment, with topline data expected in the fourth quarter of 2025. Key highlights from the ADA presentation include: Efficacy Statistically significant and dose-dependent weight loss up to 5.5% over 28 days with QD dosing Dose related increase in weight loss with 67% of patients losing 5% or more body weight at top dose Unique pharmaceutical properties result in flat PK curve allowing 24hr target coverage with QD dosing and effective half-life of 9-10 hours Higher gut vs. plasma exposures and low free fraction drives meaningful weight loss without sacrificing tolerability Safety Well-tolerated despite rapid dose titration every three days No treatment related interruptions, reductions, discontinuations at any dose >95% of GI AEs were mild despite rapid titration No meaningful changes in liver enzymes, vital signs or ECGs Tolerability and ease of use Simplest dose titration amongst GLP1-RA therapies Dosing with or without food Can be administered with PPIs, H2RA and/or antacids The presentations and viewing detail are listed below: Presentation Title: Effect of Oral Small Molecule GLP-1 Receptor Agonist TERN-601 in Healthy Participants with Obesity or Overweight – A First-in-Human Study Abstract Number: 307-OR Presentation Date and Time: Monday, June 23, 2025; 2:30-2:45 PM CT Session Name: Early Phase, Post Hoc, and Subgroup Analyses from Clinical Trials with lncretin-Based Therapies-Take 2 Presenter: Cara H. Nelson, Terns Pharmaceuticals, Foster City, CA, USA Presentation Title: No Effect of Food or Proton Pump Inhibitor on the Pharmacokinetics of TERN-601, an Oral Small Molecule GLP-1 Receptor Agonist Abstract Number: 767-P Presentation Date and Time: Sunday Jun 22, 2025; 12:30 PM - 1 :30 PM CT Session Name: Clinical Therapeutics-lncretin-Based Therapies Presenter: Cara H. Nelson, Terns Pharmaceuticals, Foster City, CA, USA About the TERN-601 Phase 1 Trial The Phase 1 trial was a randomized, double-blind, placebo-controlled single and multiple-ascending dose (SAD and MAD) trial to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of TERN-601 in healthy adults with obesity or overweight. The trial consisted of two parts. Part 1 (SAD) was a single ascending dose study that evaluated five TERN-601 dose levels in healthy participants with a Body Mass Index (BMI) of ≥ 25 kg/m2 and < 40 kg/m2. The starting TERN-601 dose was 30 mg, with subsequent dose levels based on review of emerging safety and PK data from prior cohorts. In Part 2 (MAD) of the trial, obese and overweight healthy adults were enrolled in cohorts that included titration of TERN-601 administered for 28 days at doses selected based on data from Part 1 (SAD). Part 2 included healthy participants with a BMI of ≥ 27 kg/m2 to < 40 kg/m2. The primary endpoint of the trial was to evaluate safety and tolerability of TERN-601 administered once-daily for 28 days. Secondary endpoints included PK, efficacy as measured by body weight loss following 28 days of treatment with TERN-601, and other exploratory markers. About FALCON Phase 2 Trial FALCON is an ongoing U.S.-based, multicenter, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of TERN-601, with once-daily dosing with or without food in adults with obesity or who are overweight, without diabetes (BMI ranges from ≥30 to <50 kg/m2 or ≥27 to <30 kg/m2 with at least one weight-related comorbidity). Patients are randomized to one of four active cohorts (n=30 per cohort): 250 mg, 500 mg, 500 mg slow titration, 750 mg or placebo. The primary endpoint is percent change from baseline in body weight compared to placebo over 12 weeks and secondary endpoints include safety, tolerability and proportion of patients achieving 5% weight loss or greater. About Terns Pharmaceuticals Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns' pipeline contains three clinical stage development programs including an allosteric BCR-ABL inhibitor, a small-molecule GLP-1 receptor agonist, a THR-β agonist, and a preclinical GIPR modulator discovery effort, prioritizing a GIPR antagonist nomination candidate. For more information, please visit: Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements about the Company within the meaning of the federal securities laws. Forward-looking statements include statements related to or in connection with the novelty and growth of the Company's intellectual property portfolio; expectations, timing and potential results of the clinical trials and other development activities of the Company and its partners, including with respect to the FALCON trial; the potential indications to be targeted by the Company with its small-molecule product candidates; the therapeutic potential of the Company's small-molecule product candidates; the potential for the mechanisms of action of the Company's product candidates to be therapeutic targets for their targeted indications; the potential utility and progress of the Company's product candidates in their targeted indications, including the clinical utility of the data from and the endpoints used in the Company's clinical trials; the potential differentiation of the Company's small-molecule product candidates compared to similar or competitive products or product candidates; the Company's clinical development plans and activities, including the results of any interactions with regulatory authorities on its programs; the Company's expectations regarding the profile of its product candidates, including efficacy, tolerability, safety, metabolic stability and pharmacokinetic profile and potential differentiation as compared to other products or product candidates; the Company's plans for and ability to continue to execute on its current development strategy, including potential combinations involving multiple product candidates; and the Company's expectations with regard to its cash runway and sufficiency of its cash resources. All statements other than statements of historical facts contained in this press release, including statements regarding the Company's strategy, future financial condition, future operations, future trial results, projected costs, prospects, plans, objectives of management and expected market growth, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as 'believe, 'develop', 'expect', and 'objective' and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. The Company has based these forward-looking statements largely on its current expectations, estimates, forecasts and projections about future events and financial trends that it believes may affect its financial condition, results of operations, business strategy and financial needs. In light of the significant uncertainties in these forward-looking statements, you should not rely upon forward-looking statements as predictions of future events. These statements are subject to risks and uncertainties that could cause the actual results and the implementation of the Company's plans to vary materially, including the risks associated with the initiation, cost, timing, progress, results and utility of the Company's current and future research and development activities and preclinical studies and clinical trials. These risks are not exhaustive. For a detailed discussion of the risk factors that could affect the Company's actual results, please refer to the risk factors identified in the Company's SEC reports, including but not limited to its Annual Report on Form 10-K for the year ended December 31, 2024, and subsequent Quarterly Reports on Form 10-Q. Except as required by law, the Company undertakes no obligation to update publicly any forward-looking statements for any reason. Contacts for Terns InvestorsKaytee Bock Zafereoinvestors@ MediaJenna UrbanCG Lifemedia@
